

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) Page 1 of 3	ATTY. DOCKET NO. PC11897B	SERIAL NO. 10/613,988
	APPLICANT Robert J. Chambers, et. al.	
	FILING DATE July 2, 2003	GROUP 1625

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
RO	US	4	8	6	1	8	9	1	29 Aug 89	Saccomano, Nicholas A., et al	546	194	
RO	US	4	2	7	0	9	4	6	2 Jun 81	Gutman, Arnold D.	71	94	
RO	US	4	6	9	2	1	8	5	8 Sep 87	Michaely, William J.	71	94	
RO	US	5	5	5	2	4	3	8	3 Sep 96	Christensen, Siegfried B. IV	514	520	
RO	US	5	6	0	2	1	5	7	11 Feb 97	Christensen, Siegfried B. IV	514	362	
RO	US	5	6	1	4	5	4	0	25 Mar 97	Christensen, Siegfried B. IV	514	362	
RO	US	5	8	6	3	9	2	6	26 Jan 99	Christensen, Siegfried B. IV, et al	514	277	
RO	US	5	9	2	2	5	5	7	13 Jul 99	Pon, Douglas J.	435	21	
RO	US	6	3	8	0	2	1	8	30 Apr 02	Marfat, Anthony, et. al	514	326	

FOREIGN PATENT DOCUMENTS


DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
RO	WO	9	8	1	8	7	9	6	7 May 98	International	C07D	471/04		
RO	WO	9	8	4	5	2	6	8	15 Oct 98	International	C07D	213/82		
RO	WO	9	8	4	5	6	2	8	15 Oct 98	International	F16K	3/02		
RO	WO	9	9	1	8	7	9	3	22 Apr 99	International	A01N	43/38		
RO	WO	9	5	0	0	1	3	9	5 Jan 95	International	A61K	31/275		
RO	WO	9	9	2	0	6	2	5	29 Apr 99	International	C07D	473/16		
RO	WO	9	9	2	0	2	8	0	29 Apr 99	International	A61K	31/52		
RO	WO	0	1	5	7	0	3	6	9 Aug 01	International	C07D	413/12		
RO	WO	0	1	5	7	0	2	5	9 Aug 01	International	C07D	405/12		
RO	GB	2	3	2	7	6	7	5	3 Feb 99	Great Britain	C07D	213/82		
RO	EP	0	5	5	0	9	0	0	28 Dec 92	EPO	A01N	43/40		X
RO	EP	0	5	0	0	9	8	9	9 Dec 98	EPO	C07K	5/06		
RO	EP	0	7	7	3	0	2	4	14 May 07	EPO	A61K	31/44		
RO	JP	7	3	0	4	7	7	5		Japanese				X
RO	FR	2	1	4	0	7	7	2		French	C07D	29/00		X

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)			ATTY. DOCKET NO. PC11897B	SERIAL NO. 10/613,988
Page 2 of 3			APPLICANT Robert J. Chambers, et. al.	
			FILING DATE July 2, 2003	GROUP 1625
<u>RA</u>			Trophy, Theodore J. et al, "Phosphodiesterase IV Inhibitors as Therapy for Eosinophil-induced Lung Injury in Asthma," Environmental Health Perspectives, Vol. 102 Suppl. 10, Dec. 1994, pp 79-84,	
<u>RA</u>			Duplantier, Allen J., et al., "Biarylcarboxylic Acids and -amides: Inhibition of Phosphodiesterase Type IV versus [³ H]Rolipram Binding Activity and Their Relationship to Emetic Behavior in the Ferret, Journal of Medicinal Chemistry," 1996, Vol. 39, No. 1, pp 120-125	
<u>RE</u>			Schneider, Herbert H, et al, "Discriminative Stimulus Properties of the Stereoisomers of the Phosphodiesterase Inhibitor Rolipram," Pharmacology Biochemistry and Behavior, Vol. 50, No. 2, 1995, pp. 211-217	
<u>RA</u>			Banner, Katherine H., et. al., "Acute versus chronic administration of phosphodiesterase inhibitors on allergen-induced pulmonary cell influx in sensitized guinea-pigs," British Journal of Pharmacology, 114, 1995, pp. 93-98	
<u>RA</u>			Barnette, Mary S., et. al., "The Ability of Phosphodiesterase IV Inhibitors to Suppress Superoxide Production in Guinea Pig Eosinophils Is Correlated with Inhibition of Phosphodiesterase IV Catalytic Activity," The Journal of Pharmacology and Experimental Therapeutics, 273, 1995 pp. 674-679	
<u>RA</u>			Wright, Kathryn, F., et al., "Differential in vivo and in vitro bronchorelaxant activities of CP-80,633, a selective phosphodiesterase 4 inhibitor," Can. J. Physiol. Pharmacol. 75, 1997, pp.1001-1008	
<u>RA</u>			Manabe, Haruhiko, "Anti-inflammatory and Bronchodilator Properties of KF19514, a Phosphodiesterase 4 and 1 Inhibitor," European Journal of Pharmacology, 332, 1997, pp. 97-107	
<u>RA</u>			Ukita, Tatsuzo, et. al., "Novel, Potent, and Selective Phosphodiesterase-4 Inhibitors as Antiasthmatic Agents: Synthesis and Biological Activities of a Series of 1-Pyridynaphthalene Derivatives, J. Med. Chem, 48, 1999, pp. 1088-1099	
<u>RA</u>			Compton, CH, et. al., "The Efficacy of Ariflo™ (SB 207499, A Second Generation, Oral PDE4 Inhibitor, In Patients with COPD, Am. J. Respir. Crit. Care Med., 159, 1999	
<u>RA</u>			Leeman, Marc M.D., et. al., "Reduction in Pulmonary Hypertension and in Airway Resistances by Enoximone (MDL 17,043) in Decompensated COPD," Chest, 91, 1987, pp. 662-6	
<u>RA</u>			Rabe, K.F., et. al., "Identification of PDE Isozymes in Human Pulmonary Artery and Effect of Selective PDE Inhibitors," Am. J. Physiol, 266 (LCMP 10), 1994, pp. L536-L543	
<u>RA</u>			Hughes, Bernadette, et. al., "PDE 4 inhibitors: the use of molecular cloning in the design and development of novel drugs, Drug Discovery Today, Science Direct, 2(3), 1997 pp. 89-101	
<u>RA</u>			Banner, K.H., et. al., "The Effect of Selective Phosphodiesterase Inhibitors in Comparison with other Anti-asthma Drugs on Allergen-Induced Eosinophilia in Guinea-pig Airways," Pulmonary Pharmacology, 8, 1995, pp. 37-42	
<u>RA</u>			Raeburn, David, et.al., "Anti-inflammatory and bronchodilator properties of RP 73401, a novel and selective phosphodiesterase typed IV inhibitor," Br. J. Pharmacol., 113, 1994, pp. 1423-1431	
<u>RA</u>			Karlsson, J.A., et. al., "Anti-Inflammatory Effects of the Novel Phosphodiesterase IV Inhibitor RP 73401," Int. Arch Allergy Immunol, 107, 1995, pp. 425-426	
<u>RA</u>			Escott, K.J., et. al., "Pharmacological Profiling of Phosphodiesterase, 4 (PDE4) Inhibitors and Analysis of the Therapeutic Ratio in Rats and Dogs, Br. J. Pharmacol, 123 (Proc suppl.) 1998 40P	
<u>RA</u>			Landells, L.J., et. al., "Oral Administration of the Phosphodiesterase (PDE) 4 Inhibitor, V11294A Inhibits Ex-Vivo Agonist-induced Cell Activation," Eur. Resp. J., 12 (Suppl. 28), 362s, 1998, P2393	
<u>RA</u>			Gale, D.D., et. al., "Pharmacodynamic-Pharmacokinetic (PD/PK) Profile of the Phosphodiesterase (PDE)4 Inhibitor, V11294A, in Human Volunteers," Am. J. Respir. Crit Care Med., 159, A611, 1999, pp A108	
<u>RA</u>			Montana, J., et. al., "Activity of D4418, A Novel Phosphodiesterase 4 (PDE4) Inhibitor, Effects in Cellular and Animal Models of Asthma and Early Clinical Studies," Am. J. Respir. Crit., Care Med., 159, A108, 1999, pp A624	
<u>RA</u>			Cavalla, D., et. al., "Activity of V11294A, A Novel Phosphodiesterase 4 (PDE4) Inhibitor, In Cellular and Animal Models of Asthma," Am. J. Respir. Crit. Care Med. 155, 1997, pp A660	
<u>RA</u>			Pascal, Y., et. al., "Synthesis and Structure-activity Relationships of 4-oxo-1 phenyl-3,4,5,7-Tetrahydro-[1,4]Diazepino[6,7,1-H]Indolines: Novel PDE4 Inhibitors," 215 th ACS, MEDI, 50, 1998	
<u>RA</u>			Burnouf, C., et. al., "Pharmacology of the Novel Phosphodiesterase Type 4 Inhibitor, CI-1018," 215 th ACS, MEDL 008, 1998	
<u>RA</u>			Mueller, George W., et. al., "N-Phthaloyl-β- Aryl- β- Amino Derivatives Potent TNF-α And PDE4 Inhibitors, MEDI, 299, 1999	

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) Page 3 of 3		ATTY. DOCKET NO. PC11897B	SERIAL NO. 10/613,988
		APPLICANT Robert J. Chambers, et. al.	
		FILING DATE July 2, 2003	GROUP 1625

RD		Mueller, George W., et. al., "Thalidomide Analogs and PDE4 Inhibition," Bioorganic & Medicinal Chemistry Letters, 8, 1998 pp. 2669-2674
RD		Takayama, K., "Synthetic Studies on Selective Type IV Phosphodiesterase (PDE IV) Inhibitors," MEDI 245, 1997
RD		Gordon, T., et. al., "Anti-Inflammatory Effects of a PDE4 Inhibitor in a Rat Model of Chronic Bronchitis," Am. J. Respir. Crit. Care Med., 159, A33, 1999
RD		Perrier, Helene, et. al., "Substituted Furans as Inhibitors of the PDE4 Enzyme," Bioorganic & Medicinal Chemistry Letters 9, 1999, pp. 323-326
RD		Groneberg, Robert D., et. al., "Dual Inhibition of Phosphodiesterase 4 and Matrix Metalloproteinases by an (Arylsulfonyl)hydroxamic Acid Template," Journal of Medicinal Chemistry, 1999, Vol. 42, No. 4, pp. 541-544
RD		Fujimura, Masaki, et. al. Bronchoprotective Effects of KF-19514 and Cilostazol in Guinea Pigs In Vivo," European Journal of Pharmacology, 327, 1997, pp. 57-63
RD		Manabe, Haruhiko, et. al., "KF19514, a Phosphodiesterase 4 and 1 Inhibitor, Inhibits PAF-Induced Lung Inflammatory Responses by Inhaled Administration in Guinea Pigs," International Archives of Allergy-Immunology, 1997, 114, pp. 389-399
RD		Suzuki, Fumio, et. al., "New Bronchodilators. 3. Imidazo[4,5-c][1,8]naphthyridin-4(5H)-ones," Journal of Medicinal Chemistry, 1992, Vol. 35, No. 26, pp. 4866-4874
RD		Matsuura, Akihiro, et. al., "Substituted 1,8-Naphthyridin-2(1H)-ones as Selective Phosphodiesterase IV Inhibitors," Biol. Pharm. Bull. Vol. 17(4), 1994, pp. 498-503
RD		Manabe, Haruhiko, et. al., "Pharmacological properties of a New Bronchodilator, KF17625," Jpn. J. Pharmacol., 58 (Suppl 1), 1992 pp. 238
RD		Montana, John G., et. al., "PDE4 Inhibitors: New Xanthine Analogues," Bioorganic & Medicinal Chemistry Letters 8, 1998, pp. 2925-2930
RD		Merz, Karl-Heinz, et. al., "Synthesis of 7-Benzylamino-6-chloro-2-piperazino-4-pyrrolidinopteridine and Novel Derivatives Free of Positional Isomers. Potent Inhibitors of cAMP-Specific Phosphodiesterase and of Malignant Tumor Cell Growth," Journal of Medicinal Chemistry, Vol. 41, No. 24, 1998, pp. 4733-4743
RD		Danhaive, P., et. al., "UCB29936, A Selective Phosphodiesterase Type IV Inhibitor; Therapeutic Potential In Endotoxic Shock," Am. J. Respir. Crit. Care Med., 159, A611, 1999
RD		Tian, Gaochao, et. al., "Dual Inhibition of Human Type 4 Phosphodiesterase Isostates by (R*,R*)(±)-Methyl 3-Acetyl-4-[3-(cyclopentyloxy)-4-methoxyphenyl]-3-methyl-1-pyrrolidinecarboxylate," Biochemistry, 37(19), 1998 pp. 6894-6904
RD		Norman, Peter, "PDE4 Inhibitors 1999," Exp. Opin. Ther. Patents 9(8) 1999, pp. 1101-1118
RD		Dyke, Hazel J. & Montana, John G., "The Therapeutic Potential of PDE4 Inhibitors," Expert Opinion on Investigational Drugs, 8(9), 1999, pp. 1301-1325
RD		XP-002066969, Vinivk, Fredric J., et. al., "Nicotinamide Ethers: Novel Inhibitors of Calcium-Independent Phosphodiesterase and [3H]Rolipram Binding," Journal of Medicinal Chemistry, Vol. 34, No. 1., 1991, pp. 86-89

EXAMINER 	DATE CONSIDERED 9/13/04
--	-----------------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.